Beaverton, OR, United States
PAYLESS COMPOUNDERS, LLC recalls
1 recall recorded since 2018, most recently on 6 March 2026. 1 is listed as ongoing. Status and classification are as published by the FDA.
Recalls1
Ongoing (FDA)1
Terminated or completed0
Class I (FDA)0
Ongoing Class II Drugs
- Recall started
- 6 March 2026
- Reason
- Lack of Assurance of Sterility
- Distribution
- OR
- Initiated
- Voluntary: Firm initiated
- Recall number
- D-0471-2026
- Semaglutide-Glycine-Cyanocobalamin Injectable, 2.5 mg, 5 mg, 1 MG/ML, 0.5 mL vials, Rx only, Northwest Compounders, Beaverton, OR
A terminated FDA recall means the FDA has determined that all reasonable efforts to remove or correct the product have been made. What statuses mean.